p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01789060

Enrollment

262

Registered

2013-02-11

Start date

2012-12-31

Completion date

2013-02-28

Last updated

2013-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Lymphoma, P13K-AKT Pathway Deregulation

Brief summary

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Detailed description

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B \[PKB\]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers. However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Interventions

OTHERp-AKT immunohistochemical staining

p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

17 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification; 2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.

Exclusion criteria

1\. Primary central nervous system lymphoma was excluded in this study

Design outcomes

Primary

Measure	Time frame
Difference of overall survival according to p-AKT status in malignant lymphoma	study entry

Secondary

Measure	Time frame
Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)	study entry

Other

Measure	Time frame
Subgroup analysis of overall survival according to International Prognostic Index risk groups	study entry

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026